ANI PHARMACEUTICALS INC (ANIP) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for ANI PHARMACEUTICALS INC (ANIP): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 71/100 — a percentile rank of ANI PHARMACEUTICALS INC’s fundamentals against Manufacturing peers, weakest on financial health. A quality ranking, not a price prediction.
| Market cap | $1.7B |
| P / E | 16.8× |
| P / S | 1.7× |
| EV / EBITDA | 8.1× |
| Gross margin | 60.4% |
| Operating margin | 15.4% |
| Net margin | 11.1% |
| Return on equity | 16.7% |
| ROIC | 13.5% |
| Revenue growth | 30.9% |
| Debt / equity | 1.0× |
| Dividend yield | 0.0% |
Is ANI PHARMACEUTICALS INC overvalued? P/E looks fair vs its 5-year range; P/S looks undervalued vs its 5-year range; EV/EBITDA looks undervalued vs its 5-year range; P/B looks fair vs its 5-year range.
Independent of the events above — derived from ANI PHARMACEUTICALS INC’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact